A2A antagonist

May 17, 2019

First Patients Dosed in iTeos’ Experimental A2A Receptor Antagonist Trial for Solid Tumors

News

iTeos Therapeutics’ Phase 1/1b clinical trial testing its experimental A2A receptor antagonist, EOS100850, has dosed the first group of patients with advanced solid tumors, the company announced. “I am tremendously ... Read more

July 7, 2016July 7, 2016

First Patient Dosed in Phase 1 Trial of Immuno-Oncology Treatment for Specific Cancers

News

AstraZeneca notified its partner Heptares Therapeutics that the first patient has been dosed in a Phase 1 clinical trial with immuno-oncology drug HTL1071 (AZD4635), initiating a $10 million payment from AstraZeneca. ... Read more